Inflammation in children with cystic fibrosis: contribution of bacterial production of long-chain fatty acids

Erin Felton1, Aszia Burrell2, Hollis Chaney3,4, Iman Sami3,4, Anastassios C. Koumbourlis3,4, Robert J. Freishtat2,3,5, Keith A. Crandall6 and Andrea Hahn7,2,3,7

BACKGROUND: Cystic fibrosis (CF) affects >70,000 people worldwide, yet the microbiologic trigger for pulmonary exacerbations (PExs) remains unknown. The objective of this study was to identify changes in bacterial metabolic pathways associated with clinical status.

METHODS: Respiratory samples were collected at hospital admission for PEx, end of intravenous (IV) antibiotic treatment, and follow-up from 27 hospitalized children with CF. Bacterial DNA was extracted and shotgun DNA sequencing was performed. MetaPhlAn2 and HUMAnN2 were used to evaluate bacterial taxonomic and pathway relative abundance, while DESeq2 was used to evaluate differential abundance based on clinical status.

RESULTS: The mean age of study participants was 10 years; 85% received combination IV antibiotic therapy (beta-lactam plus a second agent). Long-chain fatty acid (LCFA) biosynthesis pathways were upregulated in follow-up samples compared to end of treatment: gondoate (p = 0.012), oleate (p = 0.048), palmitoleate (p = 0.043), and pathways of fatty acid elongation (p = 0.012). Achromobacter xylosoxidans and Escherichia sp. were also more prevalent in follow-up compared to PEx (p < 0.001).

CONCLUSIONS: LCFA may be associated with persistent infection of opportunistic pathogens. Future studies should more closely investigate the role of LCFA production by lung bacteria in the transition from baseline wellness to PEx in persons with CF.

IMPACT:
- Increased levels of LCFA are found after IV antibiotic treatment in persons with CF.
- LCFA have previously been associated with increased lung inflammation in asthma.
- This is the first report of LCFA in the airway of persons with CF.
- This research provides support that bacterial production of LCFA may be a contributor to inflammation in persons with CF.
- Future studies should evaluate LCFA as predictors of future PExs.

INTRODUCTION
Cystic fibrosis (CF) is an autosomal recessive disease affecting >30,000 people in the United States and 70,000 people worldwide.1,2 Lung disease in CF patients is characterized by chronic and intermittent acute lung infections. Sequela of these infections lead to an increase in respiratory symptoms accompanied by an acute decrease in lung function known as pulmonary exacerbations (PExs).3 Staphylococcus aureus and Pseudomonas aeruginosa remain the most common bacterial pathogens identified in routine culture and are thought to contribute to both lung inflammation and PEx.2,4 PEx occurs in patients with CF at all ages, and while advances in pulmonary and antibiotic therapy continue to extend the life of CF patients, PExs are still the main cause of morbidity, mortality, and decreased quality of life.1,3

For the past 15 years, 16S amplicon sequencing has been a commonly used culture-independent research technique to characterize the airway microbiome in CF patients.6 Through leveraging the phylogenetic data from 16S amplicon sequencing, we can characterize CF airway pathogens and now know that the CF lung microbial community is more diverse and complicated than previously thought.7,8 While some studies have shown a change in community structure to be associated with transitions between wellness, PEx, and following antibiotic treatment,6,10 others have not seen significant differences.11 Thus, simply sequencing to identify the bacteria present within the airway is likely insufficient to fully understand how and why bacteria within the airway can trigger PEx and how antibiotics affect the bacterial response.

While 16S amplicon sequencing can quantify the basic community composition and taxonomic profile of the CF lung, more recent studies for characterizing airway pathogens have used an unbiased whole-genome sequencing (WGS) approach.12-14 These early studies using next-generation sequencing (NGS) sequencing to
characterize the airway have yielded greater insights into the species specificity of the lung microbiome, while little is still known about the functional genetics and antibiotic resistance mechanisms of the microbial populations and which bacterial functional pathways are associated with stages of CF lung disease. To better understand the relationship between the CF microbiome and changes in clinical status over time, including baseline wellness, PEx, and during and following antibiotic treatment, WGS coupled with metagenomic analyses of the CF airway can be used to investigate the bacterial functional profile, which aims to quantify the gene and metabolic pathway content contributed by known and uncharacterized microbiome community members.

The primary objective of this study was to identify changes in bacterial metabolic pathways associated with clinical status and intravenous (IV) antibiotic exposure (specifically, hospitalization for PEx, end of antibiotic treatment, and follow-up). The secondary objectives were to compare the metabolic changes with changes in bacterial species and antibiotic resistance. Our hypothesis is that significant differences in the bacterial metabolic profile are detectable between clinical status independent of differences associated with community composition. These findings will provide insight into the drivers associated with the transition between clinical status and identify opportunities for further study to improve management of PEx.

METHODS

Study design

This was a single-center, prospective, longitudinal cohort study of persons ≤ 18 years of age with CF (positive genotype and/or sweat chloride regulator genotype, weight, height, medications, and age, sex, race/ethnicity, cystic fibrosis transmembrane conductance regulator genotype, weight, height, medications, and results of pulmonary function tests (PFTs) and respiratory cultures.

Respiratory sample processing

Collected respiratory samples were stored at 4 °C up to 72 h before sample processing. OP swab specimens were collected using an Eswab with Amies media (Copan). Spontaneous sputum samples were collected in a sterile specimen cup. Sputum samples were homogenized by mixing 1:1 (v/v) with sterile normal saline and dithiothreitol (Fisher Healthcare), vortexing, and heating in a 37 °C heated bead bath for 15 min, whereas the Eswab media were transferred directly. Samples were pelleted through centrifugation (12,000 × g for 10 min), supernatants were removed, and pellets were stored at −80 °C until DNA extraction.

DNA extraction, quantity and quality determination, library prep, and sequencing

Pelleted bacterial cells were rapidly thawed and mixed with 1 mL of sterile phosphate-buffered saline. Bacterial DNA was extracted using a QIAamp DNA Microbiome kit (Qiagen), following the protocol as outlined by the company. Qubit (Thermo Fisher Scientific) was used for DNA quantification, and Bioanalyzer (Agilent) was used to verify DNA quality. Shotgun DNA sequencing was performed at the GW Genomics Core. DNA was diluted to a concentration of 10−20 ng/μL, and 5 μL were used for library construction using Nextera XT Library Prep kit (Illumina). Twelve to 15 libraries were sequenced per run on a NextSeq 500 (Illumina), using the Mid-Output 2 × 150 cycle kit, with an average of 12 million total sequences and 7.5 million aligned bacterial reads per sample.

Bioinformatic approaches

FastQC and FlexBar were utilized to trim sequences prior to downstream analyses. KneadData were used to separate human from bacterial sequences. MetaPhlAn2 was used for taxonomic profiling and bacterial metabolic pathways were determined using the HUMANn2 workflow on Colonial One (GW). A count table of bacterial species was generated by using the arguments –taxlev “s” and –t “rel_ab_w_read_stats” in our MetaPhlAn2 script. In our workflow of HUMANn2, we used MetaPhlAn2 for taxonomic profiling, ChocoPhlAn for a reference of functionally annotated species pan-genomes, and Bowtie 2 for nucleotide-level pan-genome mapping.

Remaining unmapped reads were aligned against UniRef90 as its protein reference database using DIAMOND. MetaCyc was utilized for pathway collection. Unstratiﬁed (i.e., unlinked from associated bacterial taxa) pathway abundance output tables were generated using the utility script “humann2_s-plit_stratiﬁed_table” and used in subsequent analysis. AmpRPlusPlus was used to align ﬁltered and trimmed bacterial sequences against antibiotic resistance genes in Galaxy to generate count tables of class-level resistance.

Observed species/pathways and taxonomy/pathway tables were imported into R studio v.3.6.1 for subsequent analyses using the packages DESeq2 v.1.24.0, ggplot2 v.3.2.0, phyloseq v.1.28.0, and vegan v.2.5-6. Alpha diversity was measured by the number of observed bacterial species, Shannon index, and the inverse Simpson’s index using Explicet v.2.10.5.

Statistical analyses

The normality of continuous data was tested using Shapiro–Wilk in STATA/IC (v.15.1). As FEV1 (p = 0.006), the number of observed bacterial species (p = 0.046), and the inverse Simpson’s index (p < 0.001) were skewed, square, square root, and log transformations were applied to normalize the distributions, respectively. Generalized linear models, using a Gaussian variance function and an identity link function, were then used for comparison of alpha-diversity measures between groups, controlling for repeated patient measures. Permutational analysis of variance was performed in Rstudio using the adonis function, using Bray distance matrices and strata to control for repeated samples obtained from each study participant.

Sensitivity analysis

Twenty-one of the sequenced samples used in subsequent analyses were from sputum, while 50 were from OP swabs. We collected and sequenced three sputum/OP swab pairs to understand the variability introduced by collecting different respiratory sample types within our cohort. We evaluated for differences in richness and alpha diversity and dissimilarity in community composition between the sputum/OP swab pairs. No significant differences were noted in alpha diversity between the sputum and
Study participants and clinical parameters

RESULTS

Study participants and clinical parameters

Twenty-seven study participants were followed from PEx onset, defined as hospital admission for IV antibiotic therapy, through antibiotic treatment and their next follow-up in pulmonary clinic (Table 1). Most participants were male (56%) and Caucasian (81%), with a mean age of 10 years. Most participants were not receiving any suppressive antibiotic and anti-inflammatory therapy at baseline (63%). At the time of PEx, a mean of 3.3 (SD 1.2) of the 12 Fuch’s criteria were reported per study participant. Most participants reported an increased cough (85%), with the next most commonly reported symptom being a change in sputum production (44%) followed by dyspnea (30%). The most common signs of PEx were a change in the physical exam of their chest (41%), radiographic changes consistent with infection (37%), and a decrease in their FEV1 of ≥10% (37%). The mean percent predicted FEV1 at exacerbation onset was 81.7%, while the mean percent predicted forced vital capacity (FVC) was 87.7% and the mean percent predicted forced expiratory flow 25–75 (FEF25–75) was 72.4%. The most common respiratory pathogens at PEx onset were P. aeruginosa and S. aureus, although 41% of participants only grew normal respiratory flora (a designation by our microbiology laboratory for bacteria commonly found in the upper airway, including alpha hemolytic Streptococci and other oral anaerobes).

Eighty-five percent of study participants received combination antibiotic therapy (beta-lactam plus another drug class). For the participants old enough to perform PFTs, the best FEV1 in the 6 months preceding their PEx was 96.4% (SD 16.7). The majority of study participants had an early disease stage with an FEV1 > 70% (85%, n = 23), while one study participant was considered to be at an intermediate disease stage (FEV1 between 40 and 70%). Three study participants were too young to perform PFTs. Pulmonary function was improved at the end of antibiotic treatment and follow-up compared to PEx, although not significantly (FEV1 p = 0.303, FVC p = 0.099, and FEF25–75 p = 0.267).

Sequencing results

Sequencing data were obtained for 71 of 81 study time points (three missed collection; seven failed sequencing). The mean number of sequences was 9.7 million (range 668K–21 million), and the mean number of aligned sequences was 7.9 million (range 12K–18.9 million). Four Zymo controls were run with the study samples and the mean relative abundance was significantly concordant with the expected relative abundance of the defined microbial community consisting of eight bacteria and two yeast (R² = 0.71, p = 0.002; Supplementary Table 2).

Bacterial species richness, relative abundance, and alpha-diversity measures

One hundred and ninety-five bacterial species were identified across all samples. There was an average of 34 bacterial species identified per sample (SD 19, range 2–75), and the relative abundance of the different bacterial species by sample is shown in Fig. 1. Across the whole cohort of samples, 13 species had a relative abundance of >1% and accounted for 81.6% of all reads. These included the following: Rothia mucilaginosa (26%), Veillonella unclassified (16.5%), Streptococcus salivarius (10.9%), Streptococcus parasanguinis (9.5%), Staphylococcus aureus (4.9%), Porphyromonas sp. (oral taxon 279, 2.4%), Actinomyces granventizii (2.2%), Granulicatella unclassified (1.9%), Leuconostoc lactis (1.6%), Neisseria unclassified (1.6%), Veillonella atypica (1.5%), Veillonella dispar (1.5%), and Rothia unclassified (1.2%). Alpha diversity was also measured to evaluate the balance of species within the samples and their relative abundance (Fig. 2). The average Shannon diversity index across all samples was 2.30 (SD 0.94, range 0.43–4.42), and the average inverse Simpson index was 3.81 (SD 2.33, range 1.12–13.76). While bacterial species richness and alpha diversity was decreased at the end of antibiotic treatment compared to exacerbation onset and follow-up while controlling for repeated samples obtained from the same participant, only richness was statistically significant (p = 0.027, Table 2). We also did not appreciate any differences in overall community composition based on clinical status, calculating Bray–Curtis dissimilarity while controlling for repeated samples collected from the same participant (Fig. 3).

Bacterial metabolic pathways across changes in clinical status

Generally, we found that pathways related to bacterial metabolic pathways of biosynthesis, degradation/utilization, and fermentation were differentially present based on clinical status (Fig. 4). Only a few degradation/utilization and fermentation pathways and a biosynthesis pathway were more abundant in PEx samples when compared to the end of treatment samples (Fig. 4a). Similarly, only a few pathways were more abundant in follow-up samples compared to PEx samples (a glycolysis and a fatty acid biosynthesis pathway), while an amine degradation pathway was more abundant in follow-up samples (Fig. 4b). However, we identified many fatty acid and lipid biosynthesis pathways that were present with a higher abundance in follow-up samples compared to the end of treatment samples, especially related to the synthesis and elongation of long-chain fatty acids (LCFAs) (Fig. 4c). These include phosphatidylcholine acyl editing (log2fold change −3.2, p < 0.001), fatty acid elongation (log2fold change −2.1, p < 0.001), palmitoleate biosynthesis (log2fold change −1.8, p < 0.001), oleate biosynthesis (log2fold change −1.8, p < 0.001), superpathway of fatty acid biosynthesis initiation (log2fold change −1.8, p < 0.001), octanoyl biosynthesis (log2fold change −1.6, p = 0.002), dodec-5-enoate biosynthesis (log2fold change −1.6, p = 0.002), and gondoate biosynthesis (log2fold change −1.5, p < 0.001). Sulfate assimilation/cysteine synthesis (log2fold change −4.7, p < 0.001) and sulfate reduction pathways (log2fold change −6.0, p < 0.001) were also more abundant in follow-up samples when compared to the end of antibiotic treatment samples (Fig. 4c). Other pathways differentially abundant between end of antibiotic treatment samples compared to follow-up samples included biosynthesis, degradation, and fermentation pathways (Fig. 4c).

Differential abundance of bacterial species across changes in clinical status

Many bacterial species were noted to be differentially abundant based on clinical status (Fig. 5). When comparing PEx versus end of treatment samples, we found that 42 bacterial species were significantly more likely to be present in PEx, while seven bacterial species were more likely to be present at the end of treatment (all adjusted p value < 0.05 and log2fold > 2), Fig. 5a. Interestingly, the majority of the species more likely to be present at PEx included many “normal” respiratory flora, including several Gemella sp., Neisseria sp., and Streptococcus sp. When comparing PEx versus follow-up samples, we found that eight bacterial species were more likely to be present in PEx, while ten bacterial species were more likely to be present in follow-up (all adjusted p value <0.05 and log2fold > 2), Fig. 5b. Again, most of the bacteria that were differentially abundant would be considered “normal” flora, with the exception of Achromobacter xylosoxidans, which...
Table 1. Demographics and clinical parameters of study participants

| Clinical parameters                      | n = 27 |
|-----------------------------------------|--------|
| **Sex (male/female)**                   | 15:12  |
| **Age at PEx (mean years, range)**      | 10 (1–18) |
| **Race (n, %)**                         |        |
| Caucasian                                | 22 (81%) |
| African American                         | 4 (15%)  |
| Unknown                                  | 1 (4%)   |
| **Ethnicity (n, %)**                     |        |
| Hispanic/Latino                          | 10 (37%) |
| Not Hispanic/Latino                      | 17 (63%) |
| **CF genotype (n, %)**                   |        |
| F508del homozgyous                       | 12 (44%) |
| F508del heterozygous                     | 11 (41%) |
| Other                                    | 4 (15%)  |
| **CFTR modulator use** (n, % yes)        | 7 (26%)  |
| **History of prior Pseudomonas aeruginosa infection (n, % yes)** | 18 (67%) |
| **Prior use of suppressive antibiotic/anti-inflammatory therapy (n, %)** | |
| Inhaled therapy                          | 6 (22%)  |
| Oral and inhaled therapy                 | 4 (15%)  |
| No therapy                               | 17 (63%) |
| **Oral antibiotics in the 30 days preceding initiation of IV therapy (n, % yes)** | 11 (41%) |
| **Signs/symptoms at PEx onset (n, %)**   |        |
| Cough                                    | 23 (95%) |
| Sputum production                        | 12 (44%) |
| Dyspnea                                  | 8 (30%)  |
| Fever                                    | 6 (22%)  |
| Fatigue                                  | 4 (15%)  |
| Change in sinus discharge                | 2 (7%)   |
| Sinus pain                               | 1 (4%)   |
| Anorexia                                 | 1 (4%)   |
| Hemoptysis                               | 1 (4%)   |
| 10% decrease in FEV1                     | 10 (37%) |
| 10% decrease in FEF25–75                 | 11 (41%) |
| Change in chest exam (e.g., rales)       | 11 (41%) |
| New CXR findings                         | 10 (37%) |
| **Culture results at PEx onset (n, %)**  |        |
| *Pseudomonas aeruginosa* (rough strain) | 6 (22%)  |
| *Pseudomonas aeruginosa* (mucoid strain)| 4 (15%)  |
| *Staphylococcus aureus* (MSSA)           | 4 (15%)  |
| *Staphylococcus aureus* (MRSA)           | 3 (11%)  |
| *Moraxella catarrhalis*                  | 1 (4%)   |
| *Achromobacter xylosidans*               | 1 (4%)   |
| *Stenotrophomonas maltophilia*           | 1 (4%)   |
| *Haemophilus influenza*                  | 1 (4%)   |
| Unidentified Gram-negative rod            | 1 (4%)   |
| Only normal respiratory flora            | 11 (41%) |
| **Beta-lactam antibiotics received for PEx (n, %)** | |
| Cefazidime                               | 15 (56%) |
| Piperacillin-tazobactam                  | 6 (22%)  |
| Cefepime                                 | 5 (19%)  |
| Meropenem                                | 4 (15%)  |
| Ceftriaxone                              | 2 (7%)   |

Table 1. continued

| Clinical parameters                      | n = 27 |
|-----------------------------------------|--------|
| **Other antibiotics received for PEx (n, %)** |       |
| Tobramycin                               | 17 (63%) |
| Vancomycin                               | 5 (19%)  |
| Aztreonam                                | 1 (4%)   |
| Ciprofloxacin                            | 1 (4%)   |
| Duration of antibiotic treatment (mean days ± SD) | 15.9 ± 4.7 |
| Days between date of hospitalization and date of follow-up (mean days ± SD) | 65.4 ± 36 |
| FEV1 % predicted (mean ± SD)             |        |
| PEx (n = 23)                             | 81.7 ± 19.4 |
| End of antibiotic treatment (n = 24)      | 91 ± 17.7  |
| Follow-up (n = 21)                       | 93 ± 18.2  |
| FVC % predicted (mean ± SD)              |        |
| PEx (n = 23)                             | 87.7 ± 16.6 |
| End of antibiotic treatment (n = 24)      | 95.5 ± 13 |
| Follow-up (n = 21)                       | 96.7 ± 14.4 |
| FEF25–75% predicted (mean ± SD)          |        |
| PEx (n = 23)                             | 72.4 ± 28.5 |
| End of antibiotic treatment (n = 24)      | 90.1 ± 37 |
| Follow-up (n = 21)                       | 88.8 ± 32 |

PEX: pulmonary exacerbation, CFTR: cystic fibrosis transmembrane conductance regulator.

was more abundant in follow-up samples (log2fold change of −23, adjusted p < 0.001) and Escherichia_unclassified (log2fold change of −25, adjusted p < 0.001). Lastly, when comparing end of treatment versus follow-up samples, we found that seven bacterial species were more likely to be present at the end of treatment, while 41 bacterial species were more likely to be present at follow-up (all adjusted p value < 0.05 and log2fold > |2|, Fig. 5c). Again, most of these bacterial species would be considered normal respiratory flora. However, A. xylosidans and Escherichia_unclassified remained as significantly more likely to be present in follow-up samples (log2fold change of −29 and −26, adjusted p < 0.001, respectively).

Antibiotic class-level resistance across changes in clinical status

The mean number of sequences that aligned against antibiotic resistance genes was 16K (range 0–242K). The most common antibiotic class resistance among all samples was macrolides, lincosamides, and streptogramin A and B drugs (MLS); the relative abundance of all antibiotic resistance classes is shown in Fig. 6. When exploring between changes in clinical status, we found that beta-lactam class resistance was significantly more likely to be present in treatment samples compared to PEx samples (log2fold change −1.7, adjusted p = 0.017). In addition, treatment samples

SPRINGER NATURE
Pediatric Research (2021) 90:99 – 108
were more likely to have MLS class resistance compared to follow-up samples (log2fold change 2.3, adjusted \( p = 0.025 \)), while follow-up samples were more likely to have fluoroquinolone resistance compared to treatment samples (log2fold change −1, adjusted \( p = 0.025 \)). There were no significant differences between PE exacerbation and follow-up samples.

**DISCUSSION**

In this study, we used NGS sequencing to gain insight into the functional profiles (metabolic pathways) of the CF lung community across changes in clinical status. Pathways related to biosynthesis, degradation/utilization, and fermentation, which contribute to pathogenicity and virulence, were found to be differentially abundant between respiratory samples obtained at PE exacerbation, the end of antibiotic treatment, and in follow-up. Sulfate assimilation/cysteine synthesis and sulfate reduction pathways were more prevalent in the follow-up samples when compared to the end of antibiotic treatment samples. Sulfate and cysteine metabolism play a role in extracellular phospholipase activity and flagellum-mediated surface motility in *Serratia* sp., both mechanisms of pathogenesis and virulence, and may be seen in other bacteria as well. Sulfate assimilation has also been shown to enhance microbial growth for *Escherichia coli* and other bacterial species. As these mechanisms were more predominant in the follow-up samples, it is likely that these may be related to the *Escherichia coli* sp. and allow for sustained growth after antibiotic exposure.

Perhaps, the most interesting finding was that multiple LCFA biosynthesis pathways and fatty acid elongation pathways were differentially abundant in follow-up samples compared to treatment samples. The LCFA biosynthesis pathways include dodec-5-enoate, gondoate, octanoyl-(ACP), oleate, and palmitoleate. Interestingly, we did not find any pathways specific to short-chain fatty acids (SCFA) to be differentially abundant at any time point. Free fatty acids can exert physiologic or pathophysiologic effects by acting on free fatty acid receptors in tissue. Gut-derived SCFAs have been studied extensively as yielding a protective effect on inflammation, leading to protection in inflammatory diseases across multiple organ systems. In addition, deficiencies in gut-derived SCFAs have been shown to be associated with inflammatory diseases. In contrast to SCFAs, LCFA acting on their receptors can have a pathogenic rather than protective effect in certain metabolic diseases. LCFA may not only have a role in metabolic diseases but inflammatory disease as well. As obesity is a major risk factor for asthma, current research has looked into the effect of free LCFA on airway remodeling and lung inflammation by acting on long-chain FFA receptors in the lung. LCFA have been shown to induce bronchial cell proliferation, airway remodeling, and airway smooth muscle contraction—all important factors in lung inflammation and exacerbation. While most of this research pertains to fatty acids introduced through diet or in the lab, we can speculate that LCFA produced by lung pathogens in the CF airway can have a physiologic effect like gut-derived bacterial SCFA. But instead of acting on free fatty acid receptors in tissue, Gut-derived SCFAs have been shown to be associated with inflammatory diseases. In contrast to SCFAs, LCFA acting on their receptors can have a pathogenic rather than protective effect in certain metabolic diseases.
relative abundance in our microbiome analysis study even though it was the most common pathogen identified in CF respiratory culture.\textsuperscript{8,41,42} One possible reason for this may be the methods by which CF respiratory cultures are performed in microbiology laboratories, which prioritize the growth of Gram-positive and Gram-negative aerobic organisms.\textsuperscript{43} Another possibility is the epidemiology of \textit{P. aeruginosa} in the CF population. \textit{Pseudomonas aeruginosa} is much more common in adolescents and older adults and tends to overtake the microbiome in more advanced lung disease.\textsuperscript{9,11,43,44} Our study population was younger with early disease stage, and so \textit{P. aeruginosa} should not be expected to be a dominant part of their overall bacterial community. Our study did find \textit{Gemella} sp. to be more abundant in PEx compared to end of treatment samples, which corroborates other published studies\textsuperscript{8} and suggests that \textit{Gemella} sp. may contribute to PEx in children with CF. Our findings that \textit{A. xylosoxidans} and \textit{Escherichia} sp. were more common in follow-up samples may be due in part to their antibiotic resistance profiles. \textit{Achromobacter xylosoxidans} is an opportunistic pathogen in persons with CF\textsuperscript{15} that frequently has antibiotic resistance mechanisms against beta-lactams and aminoglycosides\textsuperscript{13,46,47} which was the most commonly used antibiotic combination in our study. \textit{Escherichia coli} has also been reported to cause persistent infection in children and adults with CF\textsuperscript{48,49} which may be why we identified \textit{Escherichia} sp. more often in follow-up samples.

\begin{table}[h]
\centering
\begin{tabular}{lccc}
\hline
Clinical state & Mean & Standard error & \textit{P} value \\
\hline
Number of observed bacterial species & & & \\
Exacerbation\textsuperscript{a,b} & 36 & 3.3 & 0.027\textsuperscript{a} \\
End of antibiotic treatment\textsuperscript{c} & 23 & 3.7 & \\
Follow-up\textsuperscript{d} & 41 & 3.4 & \\
Shannon diversity index & & & \\
Exacerbation\textsuperscript{a,b} & 2.31 & 0.18 & 0.260\textsuperscript{a} \\
End of antibiotic treatment\textsuperscript{c} & 2.01 & 0.20 & \\
Follow-up\textsuperscript{d} & 2.58 & 0.18 & \\
Inverse Simpson index & & & \\
Exacerbation\textsuperscript{a,b} & 4.14 & 0.43 & 0.226\textsuperscript{c} \\
End of antibiotic treatment\textsuperscript{c} & 2.96 & 0.48 & \\
Follow-up\textsuperscript{d} & 4.28 & 0.45 & \\
\hline
\end{tabular}
\caption{Comparison of richness and alpha diversity across clinical states}
\begin{flushleft}
\textsuperscript{a}Generalized linear model following square root transform, controlling for repeated samples. \\
\textsuperscript{b}Generalized linear model, controlling for repeated samples. \\
\textsuperscript{c}Generalized linear model following log transform, controlling for repeated samples.
\end{flushleft}
\end{table}

\begin{figure}
\centering
\includegraphics[width=\textwidth]{fig2.png}
\caption{Richness and alpha-diversity measures. Number of observed species, Shannon index, and inverse Simpson Index are included. The y-axis gives the measurement, while the x-axis is organized by clinical status. E exacerbation, T treatment, F follow-up. Samples are color coded according to the study participant ID number.}
\end{figure}
Lastly, we sought to identify changes in antibiotic resistance associated with changes in clinical status in our cohort, as antibiotic exposure is known to drive antibiotic resistance. While only a few of our study participants were receiving azithromycin therapy as part of their routine care, macrolide/lincosamide/streptogramin class resistance was the most commonly identified across the cohort. Treatment samples were also more likely to have macrolide/lincosamide/streptogramin resistance, even though only a few participants were receiving azithromycin as part of their routine care.

**Fig. 3** Bray–Curtis non-metric multidimensional scaling plot. No significant difference in overall community composition was identified between changes in clinical status using permutational analysis of variance (PERMANOVA), controlling for repeated samples in the same participant ($R^2 = 0.031, p = 0.062$). E exacerbation, T treatment, F follow-up.

**Fig. 4** Differential abundance of unstratified bacterial metabolic pathways between changes in clinical status. **a** Differential abundance of bacterial pathways higher in exacerbation onset samples (right). **b** Differential abundance of bacterial pathways higher in exacerbation onset (right) and higher in follow-up samples (left). **c** Differential abundance of bacterial pathways higher in the end of antibiotic treatment samples (right) and higher in follow-up samples (left). All adjusted $p$ values are <0.05.
though neither azithromycin nor clindamycin was given during the inpatient antibiotic treatment course. Macrolide resistance in Streptococcus isolates from persons with CF has previously been reported to be as high as 50–75%, and clindamycin resistance has been reported at 25–50%.\textsuperscript{50–52} As \textgreater 20% of the total relative abundance of our cohort was \textit{Streptococcus} \textit{sp}, it is likely that this species contributed to our antibiotic class resistance findings. We also found beta-lactam resistance to be more common in
treatment samples compared to PEx samples, which was likely related to antibiotic selection pressure leading to a reduction of beta-lactam susceptible bacteria. Lastly, we found fluoroquinolone resistance to be more prevalent in follow-up samples compared to treatment samples. Interestingly, *A. xylosoxidans* frequently carry resistance genes against fluoroquinolones, and so this finding may be related to this bacteria also being more prevalent in follow-up samples. In our cohort, we found similarities between paired collections of OP swab samples may underrepresent the presence of traditional CF pathogens, such as *P. aeruginosa*. However, in our cohort, we found similarities between paired collections of different sample types in our sensitivity analysis. Future studies will collect samples from spontaneous expectorators to remove this potential bias and validate our findings. Our follow-up time point of collection was based on visits requested by the clinical team. While this typically was requested 1 month after hospitalization, there was a large variability in when the children returned to the clinic and thus in the collection of this sample. Future studies should include a research visit to ensure more consistency in the timing of the follow-up sample collection. We also did not perform a sub-analysis based on disease severity, but the majority of participants were at early disease stage or too young to complete spirometry. Future studies should include also include study participants with intermediate and advanced stage disease to assess the generalizability of our study findings. Lastly, we did not perform a sub-analysis based on infection pathogen, but given the small numbers our interpretation would have been limited.

In summary, our study findings suggest that following an IV antibiotic treatment course, LCFAs may be associated with continued inflammation due to opportunistic and persistent pathogens. Future longitudinal studies will allow for a better understanding of how the bacterial function profile after antibiotic treatment could be used to predict risk for subsequent PEx. In addition, future studies should more closely investigate the role of LCFAs production by lung bacteria in the transition from baseline wellness to PEx in persons with CF.

**DATA AVAILABILITY**

The sequence dataset supporting the conclusions of this article is available in the NCBI SRA repository under BioProject PRJNA615628. The batch and R scripts used for bioinformatic analyses have been uploaded to GitHub (github.com/alhahn/CF_functional_profilng).

**ACKNOWLEDGEMENTS**

We would like to acknowledge Alice Varughese for her contribution of data collection related to the antibiotic resistance portion of the manuscript and to Colonial One at GWU for computational time. A.H. and this work were supported by the Margaret Q. Landenberger Foundation (IBB20170207). A.H. was also supported by the Cystic Fibrosis Foundation Harry Shwachman Clinical Investigator Award (HAHN18A0-Q). E.F. was supported by the Infectious Disease Society of America, Grants for Emerging Researchers/Clinicians Mentorship Award. K.A.C. was supported by NIH National Center for Advancing Translational Sciences (R21TR002513, ULTR001876). This project was also supported by Award Number ULTR001876 from the NIH National Center for Advancing Translational Sciences. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Center for Advancing Translational Sciences or the National Institutes of Health.

**AUTHOR CONTRIBUTIONS**

A.H. conceptualized and designed the study. A.H., A.B., H.C., I.S., and A.C.K. were all involved in participant recruitment. A.H., A.B., and E.F. performed data collection.

A.B. performed sample processing and DNA extraction. A.H. and E.F. performed bioinformatic analysis. A.H., R.J.F., and K.A.C. were involved in the selection of analysis methods and interpretation of findings. E.F. and A.H. wrote the original manuscript. All authors were involved in manuscript revision and approved of the final version as written.

**ADDITIONAL INFORMATION**

**Supplementary information** The online version contains supplementary material available at https://doi.org/10.1038/s41390-021-01419-4.

**Competing interests:** The authors declare no competing interests.

**Patient consent:** Institutional Board Review (IRB) approval from Children’s National Hospital IRB was obtained prior to the beginning of the study (Pro8047, 29 Aug 2016). Written informed consent was obtained from study participants who were 18 years of age and parental permission for those who were <18 years of age. Assent was obtained from participants 7–17 years of age.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**REFERENCES**

1. MacKenzie, T. et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation Patient Registry. *Ann. Intern. Med.* **161**, 233–241 (2014).

2. Marshall, B. C. Cystic Fibrosis Foundation Patient Registry: 2018 Annual Data Report, Bethesda, Maryland. https://www.cff.org/Research/Researcher-Resources/ Patient-Registry/2018-Patient-Registry-Annual-Data-Report.pdf (2018).

3. Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am. J. Respir. Crit. Care Med.* **180**, 802–808 (2009).

4. Sagel, S. D. et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. *J. Pediatr.* **154**, 183–188 (2009).

5. Wiegener, J. S. et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. *Pediatr. Pulmonol.* **48**, 666–673 (2013).

6. Rogers, G. B. et al. Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16S ribosomal DNA terminal restriction fragment length polymorphism profiling. *J. Clin. Microbiol.* **42**, 5176–5183 (2004).

7. Zhao, J. et al. Decade-long bacterial community dynamics in cystic fibrosis airways. *Proc. Natl Acad. Sci. USA* **109**, 5809–5814 (2012).

8. Carmody, L. A. et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. *Ann. Am. Thorac. Soc.* **10**, 179–187 (2013).

9. Zemanick, E. T. et al. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations. *PLoS ONE* **8**, e62917 (2013).

10. Carmody, L. A. et al. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. *PLoS ONE* **13**, e0194060 (2018).

11. Fodor, A. A. et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. *PLoS ONE* **7**, e45001 (2012).

12. Feigelman, R. et al. Sputum DNA sequencing in cystic fibrosis: Non-invasive access to the lung microbiome and to pathogen details. *Microbiome* **5**, 20 (2017).

13. Bacci, G. et al. A different microbiome gene repertoire in the airways of cystic fibrosis patients with severe lung disease. *Int. J. Mol. Sci.* **18**, 1654 (2017).

14. Hahn, A. et al. Benchmark evaluation of true single molecular sequencing to determine cystic fibrosis airway microbiome diversity. *Front. Microbiol.* **9**, 1069 (2018).

15. Fuchs, H. J. et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. *N. Engl. J. Med.* **331**, 637–642 (1994).

16. Roehr, J. T., Dieterich, C. & Reinert, K. Flexbar 3.0 - SIMD and multicores parallelization. *Bioinformatics* **33**, 2941–2942 (2017).

17. McVerry, B. J. et al. BioBakery: a meta’omic analysis environment. *Bioinformatics* **34**, 1235–1237 (2018).

18. Segata, N. et al. Metagenomic microbial community profiling using unique clade-specific marker genes. *Nat. Methods* **9**, 811–814 (2012).

19. Francesca, E. A. et al. Species-level functional profiling of metagenomes and metatranscriptomes. *Nat. Methods* **15**, 962–968 (2018).

20. Huang, K. et al. MetaRef: a pan-genomic database for comparative and community microbial genomics. *Nucleic Acids Res.* **42**, D617–D624 (2014).

21. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* **9**, 357–359 (2012).
22. Suzek, B. E., Wang, Y., Huang, H., McGarvey, P. B. & Wu, C. H. UniRef clusters: a comprehensive and scalable alternative for improving sequence similarity searches. Bioinformatics 31, 926–932 (2015).

23. Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using DIAMOND. Nat. Methods 12, 59–60 (2014).

24. Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Res. 46, D633–D639 (2018).

25. Lakin, S. M. et al. MEGARes: an antimicrobial resistance database for high throughput sequencing. Nucleic Acids Res. 45, D574–D580 (2017).

26. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

27. Robertson, C. E. et al. Explanet: Graphical user interface software for metadata-driven management, analysis and visualization of microbiome data. Bioinformatics 29, 3100–3101 (2013).

28. Anderson, M. T., Mitchell, L. A., Sintsova, A., Rice, K. A. & Mobley, H. L. T. Sulfur assimilation alters flagellar function and modulates the gene expression landscape of Serratia marcescens. mSystems 4, e00285–19 (2019).

29. Caspi, R. et al. The MetaCyc database of metabolic pathways and enzymes. Nucleic Acids Res. 31, 55–59 (2003).

30. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).

31. Li, L., Ma, L. & Fu, P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 8, 103–125 (2014).

32. Ding, Y. et al. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites on immune regulation and autoimmunity. Immunity 154, 230–238 (2018).

33. Kowano, Y., Suzuki, K. & Ohtsu, I. Current understanding of sulfur assimilation metabolism to biosynthesize l-cysteine and recent progress of its fermentative overproduction in microorganisms. Appl. Microbiol. Biotechnol. 102, 8203–8211 (2018).

34. Li, L., Ma, L. & Fu, P. Gut microbiota-derived short-chain fatty acids and kidney diseases. Drug Des Devel Ther. 11, 3531–3542 (2017).

35. Haase, S., Haghiakia, A., Wilck, N., Müller, D. N. & Linker, R. A. Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunity 154, 230–238 (2018).

36. Ratajczak, W. et al. Immunomodulatory potential of gut microbiome-derived short-chain fatty acids (SCFAs). Acta Biochim. Pol. 66, 1–12 (2019).

37. Yonezawa, T. et al. Free fatty acids-sensing G protein-coupled receptors in drug targetting and therapeutics. Curr. Med. Chem. 20, 3855–3871 (2013).

38. Mizu, K., Matoba, A., Shibata, S., Masaki, E. & Emala, C. W. S. Obesity-induced asthma: role of free fatty acid receptors. Jpn Dent. Sci. Rev. 35, 103–107 (2019).

39. Kimura, I., Ichimura, A., Ohue-Kitano, R. & Igarashi, M. Free fatty acid receptors in health and disease. Physiol. Rev. 100, 171–219 (2020).

40. Mizia, K. et al. Novel identification of the free fatty acid receptor FFA1 that promotes contraction in airway smooth muscle. Am. J. Physiol. 309, L970–L982 (2015).

41. Matoba, A. et al. The free fatty acid receptor 1 promotes airway smooth muscle cell proliferation through MEK/ERK and PI3K/Akt signaling pathways. Am. J. Physiol. 314, L333–L348 (2018).

42. Wendell, S. G., Baffi, C. & Holguin, F. Fatty acids, inflammation, and asthma. J. Allergy Clin. Immunol. 133, 1255–1264 (2014).

43. Moran Losada, P. et al. The cystic fibrosis lower airways microbial metagenome. Eur. Respir. Rev. 2, 0096–02015 (2016).

44. van Der Gast, C. J. et al. Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J. 5, 780–791 (2011).

45. Zemanick, E. T. & Hoffman, L. R. Cystic fibrosis: microbiology and host response. Pediatr. Clin. N. Am. 63, 617–636 (2016).

46. Zemanick, E. T. et al. Airway microbiota across age and disease spectrum in cystic fibrosis. Eur. Respir. J. 50, 1700832 (2017).

47. De Baets, S. F., Schelstraete, P., Van Daele, S., Haerynck, F. & Vaneechoutte, M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J. Cyst. Fibros. 6, 75–78 (2007).

48. Hu, Y. et al. Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans. Antimicrob. Agents Chemother. 59, 1152–1161 (2015).

49. Hahn, A. et al. Antibiotic multidrug resistance in the cystic fibrosis airway microbiome is associated with decreased diversity. Helminth 4, e00795 (2018).

50. Edwards, B. D. et al. Clinical outcomes associated with escherichia coli infections in adults with cystic fibrosis: a cohort study. Open Forum Infect. Dis. 7, ofz476 (2019).

51. Barillon, P. et al. Prevalence and persistence of Escherichia coli in the airways of cystic fibrosis patients-an unrecognized CF pathogen? Int. J. Med. Microbiol. 304, 415–421 (2014).

52. Thornton, C. S. et al. Antibiotic susceptibility and molecular mechanisms of macrolide resistance in streptococci isolated from adult cystic fibrosis patients. J. Med. Microbiol. 64, 1375–1386 (2015).

53. Tazumi, A. et al. Molecular characterization of macrolide resistance determinants [erm (B) and mef (A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J. Antimicrob. Chemother. 64, 501–506 (2009).

54. Grinnis, R. W. et al. Macrolide and clindamycin resistance in Streptococcus milleri group isolates from the airways of cystic fibrosis patients. Antimicrob. Agents Chemother. 54, 2823–2829 (2010).

55. Jorth, P. et al. Direct lung sampling indicates that established pathogens dominate early infections in children with cystic fibrosis. Cell Rep. 27, 1190–1204.e3 (2019).

56. Zemanick, E. T. et al. Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods. Ann. Am. Thorac. Soc. 12, 221–229 (2015).